Deprince Race & Zollo Inc. Buys New Shares in Abbott Laboratories $ABT

Deprince Race & Zollo Inc. bought a new position in shares of Abbott Laboratories (NYSE:ABT) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 244,980 shares of the healthcare product maker’s stock, valued at approximately $25,152,000.

Several other large investors also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.6%

ABT stock opened at $92.15 on Thursday. The company has a market cap of $160.51 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.56 and a beta of 0.61. The company has a fifty day moving average price of $88.83 and a 200 day moving average price of $104.62. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ABT. Bank of America dropped their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Argus lowered their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Piper Sandler reissued an “overweight” rating and issued a $115.00 target price on shares of Abbott Laboratories in a report on Monday, June 22nd. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Finally, Jefferies Financial Group decreased their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.42.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, signaling strong upside potential and renewed Wall Street confidence. Article Title
• Positive Sentiment: Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which could expand Abbott’s CGM ecosystem and support diabetes-care sales. Article Title
• Positive Sentiment: Wells Fargo reiterated a Buy rating on Abbott Laboratories, adding to the positive analyst sentiment around the stock. Article Title
• Positive Sentiment: TipRanks highlighted Abbott as one of the dividend aristocrats that Wall Street currently likes, reinforcing the view that it remains a favored defensive healthcare name. Article Title
• Neutral Sentiment: Recent coverage compared Abbott with Intuitive Surgical, but the article was more of a broader healthcare-stock debate than a direct catalyst for Abbott’s shares. Article Title
• Neutral Sentiment: Abbott-related commentary on multi-cancer blood screening and broader healthcare trends is informative for the sector, but it does not appear to be a direct company-specific catalyst. Article Title
• Negative Sentiment: Abbott also faced headlines about a closed U.S. criminal probe into its infant-formula plant and a proposed civil settlement, which could remain a legal overhang even if the worst-case risk has eased. Article Title

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.